121 related articles for article (PubMed ID: 9017761)
1. Ibutilide: a new class III antiarrhythmic agent.
Cropp JS; Antal EG; Talbert RL
Pharmacotherapy; 1997; 17(1):1-9. PubMed ID: 9017761
[TBL] [Abstract][Full Text] [Related]
2. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
Howard PA
Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
[TBL] [Abstract][Full Text] [Related]
3. Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter.
Mountantonakis SE; Moutzouris DA; Tiu RV; Papaioannou GN; McPherson CA
Am J Emerg Med; 2006 Jul; 24(4):407-12. PubMed ID: 16787796
[TBL] [Abstract][Full Text] [Related]
4. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
Kafkas NV; Patsilinakos SP; Mertzanos GA; Papageorgiou KI; Chaveles JI; Dagadaki OK; Kelesidis KM
Int J Cardiol; 2007 Jun; 118(3):321-5. PubMed ID: 17049640
[TBL] [Abstract][Full Text] [Related]
5. [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
Zhang HC; Guo JH; Fang Q; Zheng YA; Sun YM; Zhu WQ; Wan Z; Guo JX; Ge JB; Han SM
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):798-801. PubMed ID: 15949393
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
Stambler BS; Wood MA; Ellenbogen KA
Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
[TBL] [Abstract][Full Text] [Related]
7. Ibutilide: a new class III antiarrhythmic agent.
Granberry MC
Am J Health Syst Pharm; 1998 Feb; 55(3):255-60. PubMed ID: 9492255
[TBL] [Abstract][Full Text] [Related]
8. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.
Foster RH; Wilde MI; Markham A
Drugs; 1997 Aug; 54(2):312-30. PubMed ID: 9257085
[TBL] [Abstract][Full Text] [Related]
9. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
Patsilinakos S; Christou A; Kafkas N; Nikolaou N; Antonatos D; Katsanos S; Spanodimos S; Babalis D
Am J Cardiol; 2010 Sep; 106(5):673-6. PubMed ID: 20723644
[TBL] [Abstract][Full Text] [Related]
10. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study.
Bernard EO; Schmid ER; Schmidlin D; Scharf C; Candinas R; Germann R
Crit Care Med; 2003 Apr; 31(4):1031-4. PubMed ID: 12682468
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ
Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
Ellenbogen KA; Stambler BS; Wood MA; Sager PT; Wesley RC; Meissner MC; Zoble RG; Wakefield LK; Perry KT; Vanderlugt JT
J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805
[TBL] [Abstract][Full Text] [Related]
13. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ibutilide vs. transoesophageal atrial pacing for the termination of type I atrial flutter.
Mazza A; Fera MS; Bisceglia I; Bettiol F; Pulignano G; Tanzi P; Gaudio C; Giovannini E
Europace; 2004 Jul; 6(4):301-6. PubMed ID: 15172654
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia.
Eidher U; Freihoff F; Kaltenbrunner W; Steinbach K
Pacing Clin Electrophysiol; 2006 Apr; 29(4):358-62. PubMed ID: 16650262
[TBL] [Abstract][Full Text] [Related]
16. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
[TBL] [Abstract][Full Text] [Related]
17. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.
Volgman AS; Carberry PA; Stambler B; Lewis WR; Dunn GH; Perry KT; Vanderlugt JT; Kowey PR
J Am Coll Cardiol; 1998 May; 31(6):1414-9. PubMed ID: 9581743
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm.
Zarkin GA; Bala MV; Calingaert B; VanderLugt JT
Am J Manag Care; 1997 Sep; 3(9):1387-94. PubMed ID: 10178487
[TBL] [Abstract][Full Text] [Related]
19. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
Hennersdorf MG; Perings SM; Zühlke C; Heidland UE; Perings C; Heintzen MP; Strauer BE
Intensive Care Med; 2002 Jul; 28(7):925-9. PubMed ID: 12122531
[TBL] [Abstract][Full Text] [Related]
20. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Vos MA; Golitsyn SR; Stangl K; Ruda MY; Van Wijk LV; Harry JD; Perry KT; Touboul P; Steinbeck G; Wellens HJ
Heart; 1998 Jun; 79(6):568-75. PubMed ID: 10078083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
